Viz.ai

🤝 We are excited to announce our collaboration with Sanofi and Regeneron to collaborate on a care acceleration solution for COPD. This care pathway will leverage EHR data and AI with the aim to advance the detection and management of COPD patients. COPD is the fourth leading cause of death worldwide, with an estimated 392 million people living with the disease. Together with Sanofi and Regeneron, we aim to maximize patient impact, particularly for patients who stand to benefit most from improved follow-up and care. Read the press release: https://lnkd.in/ee3eczRk

We’re proud to be working alongside Novartis US to bring intelligence, speed, and precision to breast and prostate cancer care. Together, we’re focused on helping more patients receive timely, guideline-based treatment through the power of AI. “By sharing key insights with Viz.ai, we will develop AI-powered solutions to quickly help reach patients who could benefit from guideline-based targeted treatments for prostate and breast cancer, helping significantly expedite their care.” - Rodney Gillespie, Head of Oncology, Novartis US Read more: https://lnkd.in/ejPFNqUC

🤝 We are excited to announce our collaboration with Sanofi and Regeneron to collaborate on a care acceleration solution for COPD. This care pathway will leverage EHR data and AI with the aim to advance the detection and management of COPD patients. COPD is the fourth leading cause of death worldwide, with an estimated 392 million people living with the disease. Together with Sanofi and Regeneron, we aim to maximize patient impact, particularly for patients who stand to benefit most from improved follow-up and care. Read the press release: https://lnkd.in/ee3eczRk

🤝 We're collaborating with Novartis US, a leader in oncology, to deliver AI-powered precision workflows for breast and prostate cancer care. This strategic effort will develop Viz Prostate Cancer and Viz Breast Cancer—solutions to support HCPs in delivering guideline-based treatment and timely specialist referrals, improving care coordination across complex journeys. We’re excited to take this leap in oncology, helping more patients access life-extending treatments. Read more in our announcement here 👉 https://bit.ly/3SJR56N

Viz.ai is proud to take part in a real-world osteoporosis research study sponsored by Amgen and conducted with the HCA Healthcare Research Institute. This study will assess the effectiveness of Viz Osteoporosis, a clinical decision support tool and AI Agent, in enabling earlier osteoporosis diagnosis, expediting fracture prevention strategies, and improving patient outcomes. Learn more in this blog post authored by Andrea Fox, DMSc, MHA, PA-C, Orthopedic Care Pathway Director at Viz.ai. Read the blog: https://lnkd.in/gRDwn5UB #OsteoporosisCare #ClinicalResearch #AIinHealthcare #Vizai